Amneal Pharmaceuticals
440 U.S. Highway 22 East
Suite 104
Bridgewater
New Jersey
08807
United States
Tel: 908-947-3120
Fax: 908-947-4146
Website: http://www.amneal.com/
275 articles about Amneal Pharmaceuticals
-
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
4/16/2024
Amneal Launches PEMRYDI RTU ® , the First Ready-to-Use Version of Important Oncology Injectable Medicine.
-
Amneal to Report First Quarter 2024 Results on May 3, 2024
4/10/2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open.
-
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
3/28/2024
Amneal Pharmaceuticals, Inc., a global pharmaceutical company, announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024.
-
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
3/25/2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for ciprofloxacin and dexamethasone otic suspension.
-
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
2/27/2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.
-
Amneal to Participate at Upcoming Investor Conference
2/13/2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference.
-
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
2/8/2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).
-
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
1/31/2024
Amneal Pharmaceuticals, Inc. announced that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1, 2024, prior to market open.
-
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
1/10/2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophthalmic suspension.
-
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
1/4/2024
Amneal Pharmaceuticals, Inc. announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022.
-
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
12/21/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024.
-
Amneal Announces Move to Nasdaq - December 15, 2023
12/15/2023
Amneal Pharmaceuticals, Inc. announced that it will transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange.
-
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
12/7/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
-
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
12/1/2023
Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®.
-
Amneal Reports Third Quarter 2023 Financial Results
11/7/2023
Amneal Pharmaceuticals, Inc. announced its results for the third quarter ended September 30, 2023.
-
Amneal to Participate at Upcoming November 2023 Investor Conferences
11/3/2023
Amneal Pharmaceuticals, Inc. announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the below investor conferences.
-
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
10/23/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023.
-
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
10/12/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia ® and XGEVA ® to its biosimilar pipeline.
-
Amneal to Report Third Quarter 2023 Results on November 7, 2023
10/5/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open.
-
Amneal Receives First Product Approval in China
9/6/2023
Amneal Pharmaceuticals, Inc. announced it has received its first product approval in China.